文献速递放疗物理与技术姑息放疗与转移瘤

质子治疗循证适应症的建立:当前临床试验概览

Establishing Evidence-Based Indications for Proton Therapy: An Overview of Current Clinical Trials.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2016-11-08

该研究检索并分析了全球正在进行的质子束治疗(PBT)临床试验,共识别122项活跃试验,目标入组超过42,000例患者。其中79%为干预性研究,但71%的计划入组患者来自观察性研究。最常见的试验聚焦于消化道肿瘤、中枢神经系统肿瘤和前列腺癌。结论认为PBT临床试验组合快速扩展,但多数患者进入观察性研究,未来需强调随机对照试验及第三方支付方支持。

要点

  • 全球122项活跃PBT临床试验,目标入组超42,000例患者。
  • 79%为干预性研究,但71%计划入组患者来自观察性研究。
  • 仅5项研究将患者随机分配至质子与光子治疗。

核心结论

  • PBT临床试验组合快速扩展,但多数患者将入组观察性研究而非随机对照试验。
  • 未来应聚焦优化患者入组与保留策略,强调随机对照试验并需第三方支付方支持。
  • ongoing PBT研究结果应从比较有效性及增量效益与价值角度评估。

研究设计与样本

  • 从clinicaltrials.gov和WHO国际临床试验平台注册库识别活跃PBT临床试验。
  • 提取疾病部位、年龄组、计划入组数、预计起止日期、研究类型和资金来源等数据。
  • 共识别122项活跃PBT临床试验,目标入组超过42,000例患者。

主要发现

  • 观察性研究占21%,但占计划入组患者的71%(n=29,852)。
  • 最常见试验聚焦消化道肿瘤(21%,n=26)、中枢神经系统肿瘤(15%,n=18)和前列腺癌(12%,n=15)。
  • 5项活跃研究(肺、食管、头颈、前列腺、乳腺)将患者随机分配至质子与光子治疗。
  • 3项研究将患者随机分配至质子与碳离子治疗。

关键数值与推荐

  • 干预性研究中位计划样本量为68例。
  • 观察性研究占计划入组患者的71%(n=29,852)。
  • 5项随机对照试验比较质子与光子,3项比较质子与碳离子。

临床怎么用

  • 临床医生应了解当前PBT临床试验布局,鼓励患者参与随机对照试验以建立循证适应症。
  • 在缺乏随机证据时,可参考 ongoing 观察性研究结果,但需注意比较有效性评估。

局限性

  • 仅基于注册库数据,未报告试验结果或质量评估。
  • 未提供各疾病部位具体入组标准或干预细节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To review and assess ongoing proton beam therapy (PBT) clinical trials and to identify major gaps. METHODS AND MATERIALS: Active PBT clinical trials were identified from clinicaltrials.gov and the World Health Organization International Clinical Trials Platform Registry. Data on clinical trial disease site, age group, projected patient enrollment, expected start and end dates, study type, and funding source were extracted. RESULTS: A total of 122 active PBT clinical trials were identified, with target enrollment of >42,000 patients worldwide. Ninety-six trials (79%), with a median planned sample size of 68, were classified as interventional studies. Observational studies accounted for 21% of trials but 71% (n=29,852) of planned patient enrollment. The most common PBT clinical trials focus on gastrointestinal tract tumors (21%, n=26), tumors of the central nervous system (15%, n=18), and prostate cancer (12%, n=15). Five active studies (lung, esophagus, head and neck, prostate, breast) will randomize patients between protons and photons, and 3 will randomize patients between protons and carbon ion therapy. CONCLUSIONS: The PBT clinical trial portfolio is expanding rapidly. Although the majority of ongoing studies are interventional, the majority of patients will be accrued to observational studies. Future efforts should focus on strategies to encourage optimal patient enrollment and retention, with an emphasis on randomized, controlled trials, which will require support from third-party payers. Results of ongoing PBT studies should be evaluated in terms of comparative effectiveness, as well as incremental effectiveness and value offered by PBT in comparison with conventional radiation modalities.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Mishra MV, Aggarwal S, Bentzen SM, et al. Establishing Evidence-Based Indications for Proton Therapy: An Overview of Current Clinical Trials. Int J Radiat Oncol Biol Phys. 2016. PMID: 28068231. doi:10.1016/j.ijrobp.2016.10.045

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。